Cargando…
Minimal-change disease secondary to etanercept
Etanercept is a soluble tumor necrosis factor alpha (TNFα) receptor which is widely used in the treatment of rheumatoid arthritis, psoriasis and other autoimmune inflammatory disorders. It is known for its relative lack of nephrotoxicity; however, there are reports on the development of nephrotic sy...
Autores principales: | Koya, Mariko, Pichler, Raimund, Jefferson, J. Ashley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432405/ https://www.ncbi.nlm.nih.gov/pubmed/26019819 http://dx.doi.org/10.1093/ckj/sfs081 |
Ejemplares similares
-
Minimal-change disease in adolescents and adults: epidemiology and therapeutic response
por: Keskar, Vaibhav, et al.
Publicado: (2013) -
Steroid Minimization in Adults with Minimal Change Disease
por: Koirala, Abbal, et al.
Publicado: (2021) -
Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease
por: Konstantinidis, Ioannis, et al.
Publicado: (2013) -
Minimally invasive fluoroscopic percutaneous peritoneal dialysis catheter salvage
por: Narayan, Rajeev, et al.
Publicado: (2014) -
Postdisaster Changes in Social Capital and Mental Health: A Natural Experiment From the 2016 Kumamoto Earthquake
por: Sato, Koryu, et al.
Publicado: (2020)